A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease

Inclusion Criteria:

• Capable of giving signed informed consent prior to the performance of anystudy-specific procedures.

• Able and willing to comply with all study assessments and adhere to the protocolschedule of activities.

• In the opinion of the investigator, there is a history of alcohol consumptioncompatible with either ALD or Met ALD.

• A female participant is eligible to participate after meeting additional pre-definedcriteria.

• Participants must meet predefined stable use requirements of concomitant medicationsbased on study criteria.

Exclusion Criteria:

• Meeting any definition of organ system failure as defined by the North AmericanConsortium for Study of End-stage Liver Disease (NACSELD)

• Exceeding pre-defined biochemical parameters for Alanine Aminotransferase (ALT),Aspartate aminotransferase (AST), Alkaline Phosphatase (ALP), Platelets,International normalised ratio (INR), Albumin, estimated glomerular filtration rate (eGFR), Urine albumin-creatinine ratio (UACR) or Glycosylated Hemoglobin (HbA1c).Other primary causes of liver disease based on study criteria.

• Current malignancy (except for basal cell carcinoma or uterine carcinoma-in-situ) atscreening. Participants under evaluation for possible malignancy at screening arenot eligible.

• Prior organ transplant or current listing or active consideration for organtransplant during the screening period (except for corneal transplants).

• Chronic or acute, including partial, known portal vein thrombosis.

• Prior transjugular intrahepatic portosystemic shunt (TIPSS) insertion.

• Any acute cardiovascular event including myocardial infarction, unstable angina,symptomatic heart failure, or cerebrovascular accident in the 6 months prior toscreening.

• Poorly controlled hypertension

• Clinical suspicion of rhabdomyolysis during the screening period

• Clinical suspicion of a bleeding episode during the screening period related toportal hypertension and/or low blood fibrinogen level.

• Body Mass Index (BMI) >35 kg/m2 at screening

• Any liver-related clinical event that started (onset) <8 weeks prior to Baseline (D1).